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Abstract
Background: The non-nucleoside reverse transcriptase inhibitor (NNRTI), as a major component of the highly
active antiretroviral therapy (HAART) to HIV-1 (human immunodeficiency virus type 1) infected patients, required
the development of new NNRTIs with improved resistance profile and decreased toxicity. Therefore, a series of
novel compounds, 9-phenylcyclohepta[d]pyrimidinedione derivatives (PCPs), were designed based on the chemical
structure of TNK-651, to detect anti-HIV-1 activity.
Results: 1-[(benzyloxy)methyl]-9-phenyl-cyclohepta[d] pyrimidinedione (BmPCP) among four PCPs has antiviral
activity on laboratory-adapted HIV strains (HIV-1 SF33). The results showed 50% inhibition concentrations (IC50s) of
BmPCP were 0.34 μM, 1.72 μM and 1.96 μM on TZM-bl, peripheral blood mononuclear cells (PBMCs) and MT4,
respectively. It was also effective against infection by the predominant HIV-1 isolates in China, with IC50s at low μM
levels. Its selectivity index (SI) ranged from 67 to 266 in different cells. The results of time-of-addition assay
demonstrated that BmPCP inhibited HIV-1 infection by targeting the post entry of the HIV-1 replication cycle. For
inhibition of HIV-1 reverse transcriptase activity, the IC50 values of BmPCP and NVP were 1.51 and 3.67 μM,
respectively.
Conclusions: BmPCP with a novel structure acts as a NNRTI to inhibit HIV-1 replication and can serve as a lead
compound for further development of new anti-HIV-1 drugs.
Background
Human immunodeficiency virus type 1 (HIV-1) reverse
transcriptase (RT) converts single-stranded viral RNA
into a double-stranded proviral DNA. Reverse transcrip-
tion is a necessary step in the HIV-1 replication cycle
[1]. Therefore, the inhibition of reverse transcriptase
(RT) has been one of important targets in inhibiting the
replication of HIV-1 and RT inhibitors have been the
primary therapeutic strategies in AIDS patient treatment
[2,3]. So far, two classes of RT inhibitors are available
for the treatment of HIV-1 infection: 1) nucleoside RT
inhibitors (NRTIs), such as zidovudine (AZT) and lami-
vudine (3TC), which bind directly to the active site of
RT polymerase and terminate DNA synthesis after
incorporation into the newly synthesized DNA, and 2)
non-nucleoside RT inhibitors (NNRTIs) that bind to the
hydrophobic pocket within the polymerase domain of
the p66 RT subunit, resulting in inhibition of RT activity
[4].
There are nevirapine (NVP), delavirdine (DLV), and
efavirenz (EFV) to be approved by American Food and
Drug Administration (FDA) for clinical application.
NNRTIs, a major component of the highly active antire-
troviral therapy (HAART) are included [5]. Application
of such NNRTIs in combination with nucleoside analo-
gues is highly effective in inhibiting HIV-1 replication.
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any medium, provided the original work is properly cited.However, drug resistance and side effort can cause anti-
viral therapeutic failure. In China it was reported that
the rates of resistance to NRTIs and NNRTIs were 1.6%
and 2.1%, respectively [6]. Also there was a high level of
cross-drug resistance to HIV-1 RTIs (reverse transcrip-
tase inhibitors) among Chinese AIDS (Acquired
Immune Deficiency Syndrome) patients harboring resis-
tant strains [7,8]. Therefore, it is essential to develop
new NNRTIs with improved drug resistance and
decreased toxicity.
To develop new NNRTIs, a series of 9-phenylcyclo-
hepta[d]pyrimidinedione derivatives were designed and
synthesized in the School of Pharmaceutical Sciences,
Peking University based on TNK-651, a potent NNRTI.
According to structure-activity relationships (SARs), stu-
dies of the crystal structure of the RT complex with
TNK-651 inhibitor suggest that cycloheptyl group would
adjust the aromatic ring with an effective conformation
to the plane of the pyrimidine ring, which could
improve the antiviral activity. 1-[(benzyloxy)methyl]-9-
phenyl-cyclohepta[d]pyrimidinedione (BmPCP) is from
9-phenyl-cyclohepta[d]pyrimidinedione derivatives [9].
This study aims to evaluate BmPCP anti-HIV-1 activity
and explore its putative mechanism of action.
Results
Identification of BmPCP as a RT inhibitor from 9-
phenylcyclohepta[d] pyrimidinedione derivatives
To identify new NNRTIs, a series of cyclohepta[d]pyri-
midine derivatives by using TNK-651 (Figure 1a) as a
template were designed and synthesized by the School
of Pharmaceutical Sciences, Peking University. The com-
pounds were 1-[(benzyloxy)methyl]-9-phenyl-cyclohepta
[d]pyrimidinedione(BmPCP), 1-Allyl-9-phenyl-cyclo-
hepta[d]pyrimidinedione(APCP), 1-Benzyl-9-phenyl
-cyclohepta[d]pyrimidinedione (BPCP), 1-(Ethoxy-
methyl)- 9-phenyl-cyclohepta[d] pyrimidinedione
(EPCP) and their molecular weights were 376.45, 296.36,
346.42 and 314.38 separately.(Figure 1b,c,d,e)
PCPs were tested for their inhibition on a commonly
used laboratory-adapted reference strain-HIV-1SF33 in
different cells. We found that BmPCP (molecular weight
of 376.45), which has a characteristic seven-alicyclic
benzene ring conformation (Figure 1b), exhibited the
highest inhibitory potency and lowest toxicity among all
four compounds. 50% cytoxicity concentrations (CC50s)
of BmPCP are 90.26 μM and 129.29 μM respectively
while 50% inhibition concentrations (IC50s) are 1.96 μM
and 0.34 μM on MT4 and TZM-bl cells. Selectivity
index (SI = CC50/IC50)i s8 4a n d2 6 6o na b o v eb o t h
cells. (Table 1) Therefore, BmPCP was selected for
further testing antiviral activity to different clinical HIV
isolates and target in this study.
BmPCP is effective in inhibiting viral infection on
different cells
We tested the antiviral activity of BmPCP in three cells
including peripheral blood mononuclear cells (PBMCs),
TZM-b1 and MT4 cells by using HIV-1SF33 and HIV-1
1617-1, a variant bearing K70G, 184V, 75I, 77L, I16Y
and I51M mutations, which are resistant to NRTIs (e.g.,
d4T, DDI and AZT). NVP, a NNRTI was used as a con-
trol. The result showed that BmPCP, like NVP, can
effectively inhibited HIV-1 infection including HIV-
1SF33 and HIV-1 1617-1 strains on PBMCs, TZM-b1
and MT4 cells (Table 2), but it was ineffective in inhi-
biting infection by HIV-1IIIB A17 variant which harbors
K103N and Y181C mutations and is highly resistant to
NNRTIs.
BmPCP exhibits potential inhibitory activity against
infection by primary HIV-1 isolates circulating in China
HIV-1CRF07_BC and B’ (Thailand B, a kind variant of
subtype B) are two epidemic strains in China. Further-
more, to verify the antiviral activity on China clinical
isolates, CRF07_BC and B’ were chosen. We found that
BmPCP was also effective in inhibiting infection of
PBMCs by the primary HIV-1 isolates that are
Figure 1 The structural formulas of TNK651 and PCP derivatives. (a)TNK-651, (b)1-[(benzyloxy) methyl]-9-phenyl-cyclohepta[d]
pyrimidinedione (BmPCP), (c) 1-Allyl -9-phenyl-cyclohepta[d ]pyrimidinedione(APCP), (d)1-Benzyl -9-phenyl-cyclohepta[d]pyrimidinedione(BPCP),
(e)1-(Ethoxymethyl)- 9-phenyl-cyclohepta[d]pyrimidinedione (EPCP)
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NVP (Table 3).
BmPCP has low cytotoxicity on different cells used for
testing antiviral activity
XTT assay [10] was used to test the cytotoxicity of
BmPCP on MT4 cells, human PBMCs (non-stimulated)
and TZM-bl cells. BmPCP cytotoxicity on these cells
was demonstrated as 50% or 90% cytotoxic concentra-
tion (CC50 or CC90). CC50 values are ranging from 90 to
165 μM (Table 4).
BmPCP targets the post entry of HIV-1 replication cycle
To determine the target of BmPCP during HIV-1 repli-
c a t i o n ,w ep e r f o r m e dat i m e - o f - a d d i t i o na s s a yb yu s i n g
Enfuvirtide (T20), the HIV-1 fusion inhibitor interfering
with entry of the HIV-1 virus into cells, and NVP, a
NNRTI, as controls. As shown in Figure 2, unlike T20
which exhibited no inhibitory activity when it was added
to the virus culture one hour after viral infection, both
BmPCP and NVP demonstrated antiviral activity when
they were added to the virus culture even eight hours
post-infection. These results suggest that BmPCP is
similar to NVP which inhibits HIV-1 infection by target-
ing the post entry of the HIV-1 replication cycle.
BmPCP can effectively inhibit HIV-1 reverse transcriptase
activity in vitro
To further identify the target site of BmPCP during the
HIV life cycle, the method based on ELISA RT assay was
used to detect the inhibition activity of reverse transcrip-
tase. Oligo(dT) 15 was immobilized via its 5’-terminal
phosphate to Covalink-NH microtiter plates. The biotin-
dUTP was incorporated by reverse transcriptase. The
products were detected and quantified using a colori-
metric strep- tavidin-alkaline phosphatase reporter sys-
tem. The IC50 values of BmPCP and NVP were 1.51 and
3.67 μM, respectively, indicating BmPCP directly targets
the process of HIV reverse transcriptase. (Figure 3)
Discussion
The novel cyclohepta[d]pyrimidine derivatives targeting
the non-nucleoside reverse transcriptase inhibitor
(NNRTI) binding site have been rationally designed
based on the structure of the NNRTI binding pocket.
Although extensive SARs for non-cyclic analogues (such
as MKC-442 and TNK-651) have been obtained, little or
no information was available about the annelated series.
The key point for the development of such compounds
is the right size of the annelated rings, which should not
only possess conformational flexibility, but also restrict
effectively the rotation and position of the aromatic ring
to the plane of the pyrimidine ring. According to struc-
ture-activity relationships (SARs), studies of the crystal
Table 1 The inhibitory activity of PCPs on infection by
HIV-1 SF33
Compounds Virus/Cell CC50(μM) IC50(μM) SI
a
BmPCP SF33/MT4 165.29 1.96 84
SF33/TZM-bl 90.26 0.34 266
APCP SF33/MT4 62 28.6 2.17
SF33/TZM-bl 50 1.3 38.46
BPCP SF33/MT4 132.25 114,7 1.15
SF33/TZM-bl 180 9 20
EPCP SF33/MT4 29.28 7.5 3.9
SF33/TZM-bl 22 1.6 13.75
aSelectivity index(SI) = CC50/IC50
Table 2 The inhibitory activity of BmPCP on infection in
different cells
TZM-bl PBMCs MT4
Compounds HIV-1
strain
IC50
a
(μM)
SI
b IC50
a
(μM)
SI
b IC50
a
(μM)
SI
b
BmPCP 1617-1 1.45 ±
0.21
62 1.76 ±
0.23
65 1.47 ±
0.43
128
SF33 0.34 ±
0.09
266 1.72 ±
0.37
67 1.96 ±
0.58
84
NVP 1617-1 0.16 ±
0.10
- 0.57 ±
0.08
- 0.44 ±
0.12
-
SF33 0.19 ±
0.02
- 0.69 ±
0.07
- 0.65 ±
0.23
-
a Compounds were tested in triplicate and the data are presented as means ±
SD.
b Selectivity index(SI) = CC50/IC50
Table 3 The IC50 values of BmPCP against infection by
primary HIV-1 isolates circulating in China
BmPCP NVP
HIV-1 subtype Co-
receptor
IC50
a(μM) SI
b IC50
a(μM) SI
b
AH104 B’ X4/R5 0.59 ± 0.34 153 0.007 ± 0.003 29,143
AH259 B’ R5 0.32 ± 0.15 282 0.007 ± 0.001 29,143
AH968 B’ R5 0.44 ± 0.17 205 0.058 ± 0.060 3,517
XJ257 B’/C R5 0.53 ± 0.07 170 0.211 ± 0.120 967
XJ0793 B’/C R5 0.25 ± 0.03 361 0.079 ± 0.097 2,582
XJ6291 B’/C R5 0.57 ± 0.02 158 0.186 ± 0.224 1,097
a Compounds were tested in triplicate and the data are presented as means ±
SD.
b Selectivity index(SI) = CC50/IC50
Table 4 The CC50 and CC90 values of BmPCP in different
cells
a
Cells CC50
b (μM) CC90 (μM)
b
TZM-bl 90.26 ± 2.73 207.93 ± 8.69
PBMC 114.5 ± 9.38 228.56 ± 6.40
MT4 165.29 ± 30.40 382.59 ± 53.52
aThe compound was tested in triplicate and the data are presented as means
±S D .
bXTT assay was used to determine the 50% or 90% cytotoxic concentration
(CC50 or CC90)
Huang et al. Virology Journal 2011, 8:230
http://www.virologyj.com/content/8/1/230
Page 3 of 6structure of the RT complex with TNK-651 inhibitor
suggest that cycloheptyl group would adjust the aro-
matic ring with an effective conformation to the plane
of the pyrimidine ring, which could improve the activity.
Compared with the structures of APCP, BPCP and
EPCP, BmPCP reserves the part of TNK-651and then
was identified as a potential lead compound by the inhi-
bition of viral infectivity in different cells. Selectivity
Index reached to 84 on MT4 cell and 266 on TZM-bl
cell respectively.
Here we tested the inhibitory activity of BmPCP on
infection by laboratory-adapted HIV-1 strains, including
HIV-1SF33 and HIV-1 1617-1 as well as HIV clinical
isolates circulating in China. In China, CRF07_BC and
B’ have been the most commonly transmitted HIV-1
subtypes across the country [11]. Therefore, we focused
on the inhibitory activity of BmPCP on Chinese epi-
demic HIV-1 subtype strains. The result showed that
BmPCP was effective against infection by a broad spec-
trum of HIV-1 strains, including both R5 and X4 viruses
with IC50 at low μM levels. BmPCP has antiviral activity
on laboratory-adapted HIV strains as well as clinical iso-
lates from Chinese AIDS patients.
Also similar to NVP, BmPCP inhibits HIV-1 infection
by targeting the post entry of the HIV-1 replication
cycle by time-of-additional assay. Furthermore, in vitro
HIV-1 reverse transcriptase activity assays corroborated
that BmPCP directly targets the process of HIV reverse
transcriptase. These results suggest that BmPCP may act
as a NNRTI to inhibit HIV-1 replication. BmPCP exhib-
ited low cytotoxicity to cells that were used for testing
anti-HIV-1 activity, thus having selectivity index ranging
from 60 to 360, suggesting a good potential for further
development of BmPCP as a new anti-HIV-1 drug.
Like NVP, BmPCP was much less effective against
NNRTI drug resistant strains. However, BmPCP with a
novel structure acts as a NNRTI to inhibit HIV-1 repli-
cation and can serve as a lead compound for further
development of new anti-HIV-1 drugs.
Conclusion
This study demonstrates that BmPCP has a novel struc-
ture and is effective against infection by a broad spec-
trum of HIV-1 strains, including both Chinese clinical
isolates and laboratory-adapted HIV-1 strains with IC50
at low μM levels. Similar to NVP, BmPCP could signifi-
cantly inhibited RT activity. BmPCP is a lead compound
for the probability of future drug development.
Methods
Cells, viruses, and reagents
TZM-bl and MT4 cells, viruses - HIV-1 SF33, and HIV-
1 1617-1, and anti-HIV-1 drugs - NVP and Enfuvirtide
(T20) were all obtained from the NIH AIDS Research
and Reference Reagent Program (USA). MT4 cells [12]
were maintained in RPMI 1640 medium supplemented
with 10% heat-inactivated fetal bovine serum (FBS), 100
U/ml penicillin and 100 μg/ml streptomycin. TZM-bl
were propagated in Dulbecco’s modified Eagle medium
(DMEM) containing 10% (vol/vol) FBS, 100 units/ml
penicillin, and 100 μg/ml streptomycin. PBMCs from
two HIV-1-seronegative human donors were maintained
in RPMI 1640 medium (Gibco) containing 20 U/ml of
recombinant interleukin-2 (IL-2; National Institutes of
Health; Bethesda, Maryland, USA), 1% penicillin and
streptomycin (P/S), 2 mM glutamine and 10% FBS. The
clinical viruses were isolatedf r o mp a t i e n t si n f e c t e db y
HIV-1 CRF07_BC and B’ strains in China [13].
Figure 2 Time-of-addition assay of compounds.T Z M - b lc e l l s
were infected with HIV-1SF33 at 200 TCID50. BmPCP(■), NVP(◆) and
T-20(▲), were respectively added 0, 0.25, 0.5, 1, 2, 4, and 8 hrs post-
infection. Results are the mean inhibition rate in duplicate
experiments
Figure 3 The inhibition effect of BmPCP and NVP on HIV-RT in
vitro. The inhibition rate of BmPCP and NVP are tested at the dose
of 0.2, 1, 2, 4, 8, 16 μM and the results are the mean inhibition rate
in duplicate experiments
Huang et al. Virology Journal 2011, 8:230
http://www.virologyj.com/content/8/1/230
Page 4 of 6HIV-1 inhibition assays
The inhibitory activity of BmPCP, APCP, BPCP and
EPCP on infection by laboratory-adapted HIV-1 strains
was tested in TZM-bl cells, MT4 cells or PBMCs,
respectively, as previously described [10]. TZM-bl cells
were seeded at 10
4/well and cultured in a 96-well tis-
s u ec u l t u r ep l a t eo v e r n i g h t ,f o l l o w e db ya d d i t i o no f
200 TCID50 (50% Tissue Culture Infective Dose) of
HIV-1 virus. After incubation at 37°C for 2 hrs,
BmPCP at graded concentrations was added. After
further incubation at 37°C for 48 hrs, the luciferase
activity was measured using a luciferase assay kit (Pro-
mega Corp.) according to the manufacturer’si n s t r u c -
tions. MT4 cells (4 × 10
4/well) and PBMCs (1 × 10
5/
well) were infected by addition of 200 TCID50 of HIV-
1 virus, followed by incubation for 2 hrs at 37°C before
addition of BmPCP at serial dilutions. After further
incubation at 37°C for 4 days (for MT4 cells) or 7 days
(for PBMCs), HIV-1 p24 was measured using a com-
mercial enzyme-linked immunosorbent assay (ELISA)
kit (Vironostika HIV-1 Microelisa system; BioMérieux;
Marcy l’Etoile, France). The inhibitory activity of
B m P C Po ni n f e c t i o nb yp r i m a r yH I V - 1i s o l a t e sw a s
also tested in PBMCs as described above. The percent
of inhibition and the IC50 were calculated as previously
described [10].
Cytotoxicity assay
An XTT assay, as previously described [10], was used
for assessing the cytotoxicity of BmPCP to the cells
tested for anti-HIV-1 activity. Briefly, BmPCP at graded
concentrations was added to MT4 cells, PBMCs, and
TZM-bl cells at 4 × 10
4,1×1 0
5 and 1 × 10
4 cells per
well, respectively, followed by an incubation at 37°C for
3 days. Ten microliters of CCK-8 reagent was added to
the cells. After incubation at 37°C, for 4 h to allow color
development of the XTT formazan product, the absor-
bance of each well was then read at 450 nM in a Vic-
tor2 1420 Multilabel Counter (Wallace-PerkinElmer Life
and Analytical Sciences Inc., Boston, MA). The percent
of cytotoxicity and CC50 were calculated as previously
described [10].
Time-of-addition assay
MT4 cells were seeded at 10
4/well and cultured in a 96-
well tissue culture plate overnight, followed by addition
of 200 TCID50 of HIV-1SF33. BmPCP (13.3 μM) and
the control compounds, NVP (5 μM) and T-20 (5 μM),
were respectively added 0, 0.25, 0.5, 1, 2, 4, and 8 hrs
post-infection. HIV-1 p24 was measured using a com-
mercial enzyme-linked immunosorbent assay (ELISA)
kit (Vironostika HIV-1 Microelisa system; BioMérieux;
Marcy l’Etoile, France).
Assay for inhibition of HIV-1 reverse transcriptase activity
The method was described in a previous publication
[14]. Briefly, Oligo(dT) 15 was immobilized via its 5’-
terminal phosphate to CovaLink NH microtiter plates.
The biotin-dUTP was incorporated by reverse transcrip-
tase. The products were detected and quantified using a
colorimetric streptavidin alkaline phosphatase reporter
system.
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